T-cell engager technologies
- Health
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
Ingelheim, Germany & Basel, Switzerland: Acquisition will add another key dimension to Boehringer Ingelheim’s focus on patients with difficult-to-treat solid…
Read More »